Asynthetic version of a rare toxin produced by a sea creature appears to hold promise for treating many different types of cancer while minimizing the harmful side effects of widely used chemotherapy drugs.
A study published today in the journal Science Translational Medicine describes research on a substance called diazonamide, which prevents cell division, and was isolated from a marine animal called Diazona angulata.
Led by Patrick Harran, UCLA’s Donald J. and Jane M. Cram Professor of Organic Chemistry, researchers produced a synthetic form of diazonamide that, in rodents, appears to be effective in fighting breast cancer, colon cancer and leukemia. The compound the scientists synthesized, DZ-2384, is more potent and lasts longer in the bloodstream than natural diazonamide.
According to the legendary automotive designer, the new brand will come out with a technologically advanced, premium electric car sometime in 2017.
Henrik Fisker has relaunched his namesake company, he told Bloomberg.
The charismatic Dane said his newly minted Fisker, Inc. will showcase a premium, all-electric vehicle in the second half of 2017. In a private phone call on Monday, he called it a “spiritual successor” to the Fisker Karma electric car he launched in 2012.
The NIH’s Small Business Innovation Research program funded the grant.
Neural Analytics landed a $3 million grant from the National Institutes of Health for the diagnostic and monitoring technology it’s developing for traumatic brain injury and stroke, the company reported. The NIH’s Small Business Innovation Research program funded the grant.
Los Angeles-based Neural Analytics, founded in 2013, develops technology to measure and track brain health, particularly traumatic brain injury, acute ischemic stroke, and dementia. The company is working on a portable ultrasound headset for athletes at risk of concussion.